

Cover Story
On Sept. 4, Jay Bhattacharya did something NIH directors rarely do: he appeared before the National Cancer Advisory Board, speaking directly with the NCI advisory board about hot-button policy changes taking place under his leadership at NIH.
Cancer Policy
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for September 2025
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- A new diagnostic lens—and a lasting scientific legacy
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives





















